Antibody–drug conjugates have become a major platform in precision oncology, combining the targeting ability of antibodies with the potency of cytotoxic payloads. But despite advances in linker chemistry, payload design and antibody engineering, ADC developers still face challenges around tumour penetration, payload distribution, drug–antibody ratio, systemic exposure and manufacturing consistency.
In the full article, Isogenica explores how VHH single-domain antibodies could help address some of these limitations and expand the design space for next-generation ADCs. Because VHHs are much smaller than conventional IgG antibodies, they may support deeper and more uniform tumour penetration, helping payloads reach cells that larger antibody formats can struggle to access.
The blog also looks at how the compact, modular structure of VHHs can support more controlled ADC design, including opportunities for site-specific conjugation, tailored pharmacokinetics and more consistent production.
Rather than positioning VHHs as simple replacements for conventional antibodies, the article highlights their potential as flexible building blocks for new ADC architectures — including multi-VHH, bispecific and multivalent designs that could improve selectivity and address heterogeneous antigen expression.
Read the full blog: https://isogenica.com/how-vhhs-can-redefine-the-next-generation-of-adcs/